Similar articles for PMID: 35093916

Year	Number of Results
2013	2
2014	6
2015	13
2016	12
2017	22
2018	15
2019	13
2020	15
2021	16
2022	21
2023	5
2024	0

1

Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma.

Kurashina R, Ando K, Inoue M, Izumi K, Maruyama R, Mitani K, Takenobu H, Haruta M, Iizuka T, Kamijo T, Kageyama Y. Kurashina R, et al. Anticancer Res. 2022 Feb;42(2):1131-1136. doi: 10.21873/anticanres.15576. Anticancer Res. 2022. PMID: 35093916

2

Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma.

Kadono Y, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kamijima T, Seto C, Takano A, Yotsuyanagi S, Nakagawa R, Miyagi T, Aoyama S, Asahi H, Fukuda R, Mizokami A. Kadono Y, et al. Anticancer Res. 2021 Mar;41(3):1599-1606. doi: 10.21873/anticanres.14921. Anticancer Res. 2021. PMID: 33788755

3

The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.

Ogihara K, Kikuchi E, Shigeta K, Okabe T, Hattori S, Yamashita R, Yoshimine S, Shirotake S, Nakazawa R, Matsumoto K, Mizuno R, Hara S, Oyama M, Masuda T, Niwakawa M, Oya M. Ogihara K, et al. Urol Oncol. 2020 Jun;38(6):602.e1-602.e10. doi: 10.1016/j.urolonc.2020.02.005. Epub 2020 Mar 2. Urol Oncol. 2020. PMID: 32139290

4

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.

Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R, Serretta V, Busetto GM, Scafuro C, Perdonà S, Borghesi M, Schiavina R, Cioffi A, De Berardinis E, Almeida GL, Bove P, Lima E, Ucciero G, Matei DV, Crisan N, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Mirone V, Shariat SF, Ferro M. Cantiello F, et al. Eur Urol Oncol. 2018 Oct;1(5):403-410. doi: 10.1016/j.euo.2018.06.006. Epub 2018 Jul 13. Eur Urol Oncol. 2018. PMID: 31158079

5

The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.

Huszno J, Kolosza Z, Mrochem-Kwarciak J, Rutkowski T, Skladowski K. Huszno J, et al. Oncology. 2019;97(1):7-17. doi: 10.1159/000498943. Epub 2019 May 2. Oncology. 2019. PMID: 31048577

6

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.

Kobayashi T, Ito K, Kojima T, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Ogawa O, Kitamura H, Nishiyama H. Kobayashi T, et al. Cancer Immunol Immunother. 2022 Feb;71(2):461-471. doi: 10.1007/s00262-021-03000-8. Epub 2021 Jul 7. Cancer Immunol Immunother. 2022. PMID: 34235546

7

Evaluation of the clinical value of hematological parameters in patients with urothelial carcinoma of the bladder.

Luo Y, Shi X, Li W, Mo L, Yang Z, Li X, Qin L, Mo W. Luo Y, et al. Medicine (Baltimore). 2018 Apr;97(14):e0351. doi: 10.1097/MD.0000000000010351. Medicine (Baltimore). 2018. PMID: 29620666 Free PMC article.

8

Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer.

Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, Maemura K, Okubo K, Uenosono Y, Ishigami S, Natsugoe S. Hirahara T, et al. BMC Cancer. 2019 Jul 8;19(1):672. doi: 10.1186/s12885-019-5903-y. BMC Cancer. 2019. PMID: 31286873 Free PMC article.

9

Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

Ulas A, Avci N, Kos T, Cubukcu E, Olmez OF, Bulut N, Degirmenci M. Ulas A, et al. J BUON. 2015 May-Jun;20(3):714-22. J BUON. 2015. PMID: 26214622 Free article.

10

Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.

Cho KM, Park H, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ. Cho KM, et al. Oncotarget. 2017 Jan 10;8(2):2329-2341. doi: 10.18632/oncotarget.13731. Oncotarget. 2017. PMID: 27911876 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

117 results

Results by year